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ORIGINAL ARTICLE
Structural analysis of a novel rabbit monoclonal antibody
R53 targeting an epitope in HIV-1 gp120 C4 region
critical for receptor and co-receptor binding
Ruimin Pan1, Yuxin Chen2, Michael Vaine2, Guangnan Hu2, Shixia Wang2, Shan Lu2 and Xiang-Peng Kong1
The fourth conserved region (C4) in the HIV-1 envelope glycoprotein (Env) gp120 is a structural element that is important for its
function, as it binds to both the receptor CD4 and the co-receptor CCR5/CXCR4. It has long been known that this region is highly
immunogenic and that it harbors B-cell as well as T-cell epitopes. It is the target of a number of antibodies in animal studies, which are
called CD4-blockers. However, the mechanism by which the virus shields itself from such antibody responses is not known. Here, we
determined the crystal structure of R53 in complex with its epitope peptide using a novel anti-C4 rabbit monoclonal antibody R53.
Our data show that although the epitope of R53 covers a highly conserved sequence 433AMYAPPI439, it is not available in the gp120
trimer and in the CD4-bound conformation. Our results suggest amaskingmechanism to explain howHIV-1 protects this critical region
from the human immune system.
Emerging Microbes and Infections (2015) 4, e44; doi:10.1038/emi.2015.44; published online 15 July 2015
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INTRODUCTION
The HIV-1 envelope glycoprotein (Env) gp120 initiates viral entry into
host cells by binding to its receptor CD4 and to its co-receptor CCR5/
CXCR4, and it is the major target for acquired immune deficiency
syndrome vaccine development. However, gp120 uses many decoys to
evade immune surveillance in humans, rendering the development of
a protective vaccine very challenging. Conformational masking, by
either covering immunogenic epitope regions with other domains,
or by having them adopt different conformations, is one of the decoys
gp120 uses to evade the immune responses.1,2 For example, variable
loops can often adopt different conformations, and antibodies that
recognize one conformation will not be able to effectively target
another conformation.3–5 Conformational masking can also protect
functionally conserved sites within gp120. The CD4 receptor-binding
site is protected by entropy masking,1 and the co-receptor-binding site
in the pre-fusion complex is completely buried under variable loops.6–8
CD4 receptor binding will expose the co-receptor binding site, which
is comprised of various conserved regions including the fourth con-
served region (C4). The C4 region of gp120, which consists of residues
416-4599 (HxB2 numbering10), has many important functional roles.
For example, it is directly involved in receptor binding, co-receptor
binding and co-receptor selection (tropism).11,12 Crystal structures of
gp120 complexes have revealed that residues 425 (Asn), 426 (Met),
and 427 (Trp) in the C4 region have direct contact with CD4.13 The
C4 region, together with the third variable loop (V3), is also involved
in co-receptor binding. Early mutagenesis studies indicated that resi-
dues 438 (Pro) and 441 (Gly) in the C4 region are important for CCR5
binding.14 Structural studies of gp120 in complex with CD4 and
monoclonal antibody (mAb) 412d showed that residues 439 (Ile),
440 (Arg), and 441 (Gly) in the C4 region are involved in binding
with the N-terminus of CCR5.6 A slight conformational change in the
C4 region can influence the structure of V3, and even a single amino
acid mutation in the C4 region can increase the neutralization sensi-
tivities of anti-V3 antibodies.15,16 The C4 region is also involved in co-
receptor selection, and mutations of residue 440 in the C4 region can
alter co-receptor specificity.17
The C4 region is highly immunogenic. It can induce cell-mediated
immunities in HIV-1 infected patients and in immunized animals.18,19
For example, monomeric gp120 can elicit mouse helper T-cell
immune responses reactive with a C4 peptide, named T1 (a 16-mer
containing the region of residues 428-443).18 The C4 region can also
induce humoral immune responses.20,21 In fact, the CD4 binding
region of gp120 was first identified by an anti-C4 mAb, 5C2E5, which
was raised by immunizing mice with a recombinant gp120, and its
epitope region was identified by competition with CD4 binding.11
Since then, several antibodies targeting the C4 region have been gen-
erated in animals, including rabbit polyclonal antibodies R10-12 and
R19-21 that were raised with a poliovirus chimaera expressing a region
of 17 amino acids of C4,22 mouse mAbs G3-42, G3-299, G3-508, and
G3-536 that were raised with a recombinant BH10 gp120,23,24 and rat
mAbs ICR 38.8f and ICR38.1a that were raised with the recombinant
BH10 gp120.25 One of the characteristics of these antibodies is that
they can block CD4 binding of gp120, and thus, they were collectively
named CD4-blocking antibodies.26
The C4 region was initially suggested to form amphipathic helices;19
however, crystal structures of CD4-bound gp120 molecules have
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shown that it actually forms two beta strands, numbered 20 and 21, of
the bridging sheet and loop F.13 Strand 20 is involved in CD4 binding,
while strand 21 is involved in co-receptor binding. The structures of
gp120 in complex with various mAbs showed that the C4 region could
display distinct conformations among the unliganded, CD4-bound,
and different antibody-bound states.7,13,27–29
Here, we present functional and structural characterizations of a
recently generated rabbit anti-C4 mAb, R53, which was elicited by JR-
FL gp120 using a DNA prime-protein boost regimen.30 It can neutralize
sensitive viruses quite potently but cannot neutralize tier 2 viruses. We
show here that R53 has broad cross-clade binding activities against gp120
proteins from clade A, B, C, D, and AE. We have determined crystal
structures of R53 Fab/epitope complex and R53 Fab alone, and have
structurally defined the R53 epitope. We found that this epitope harbors
a conserved motif, AMYAPPI (residues 433-439), located at the C-ter-
minus of the bridging sheet and loop F of gp120. Our data provide a
structural understanding of this immunogenic and functionally critical
region and the mechanism by which it is masked.
MATERIALS AND METHODS
Enzyme-linked immunosorbent assay (ELISA)
Gp120 proteins produced from 293F cells were coated onto 96-well
microtiter plates (Sigma-Aldrich, St. Louis, MO, USA) at 1 mg/mL in
100 mL of phosphate-buffered saline (PBS) as previously described.30
Plates were washed five times with PBS containing 0.1% Triton-X
(EWB) and blocked overnight at 4 6C in PBS containing 4% whey
and 5% powdered milk. R53, biotinylated anti-rabbit secondary anti-
body (Vector Labs BA-1000) at 1.5 mg/mL, and a streptavidin horse-
radish peroxidase construct (Vector Labs SA-5004, Burlingame, CA,
USA) at 500 ng/mL were added sequentially to the wells in a volume of
100 mL. Plates were incubated for 1 h at room temperature and washed
five times after each step with EWB and then developed for 3 min in
100 mL of a 3,395,59-tetramethylbenzidine substrate solution (Sigma-
Aldrich T3405, St. Louis, MO, USA). The reactions were stopped with
25 mL of 2N H2SO4.
Western blot
The gp120 antigens were subjected to SDS-PAGE and blotted onto
polyvinylidene fluoride (PVDF) membranes as previously described.30
PVDF membranes were blocked with 0.1% I-Block (Tropix, Bedford,
MA, USA), incubated with mAb R53 for 1 h, and subsequently reacted
with AP-conjugated goat anti-rabbit IgG at a dilution of 1:5000 for 30
min. The membranes were washed with the blocking buffer after each
step. Western-light substrate was then applied to the membranes for 5
min. X-ray films were exposed to the dried membranes and developed
using a Kodak processor.
Ab binding kinetics analysis
The binding kinetics of mAb R53 and five representative gp120s was
studied using biolayer interferometry (BLI, ForteBio Octet QKe) in a
96-well format, as previously described.30 Protein A-coated tips (ProA
sensor, ForteBio) were loaded with R53 at 10 mg/mL in the kinetics
buffer (PBS/0.1% bovine serum albumin (BSA)/0.002% Tween 20).
After capture, excess unbound antibodies were removed with a 1-min
wash using the kinetics buffer to establish a new baseline signal. Then,
the biosensor tips coated with mAb R53 were placed in wells contain-
ing the designated gp120 proteins at concentrations of 300, 100, 33.3,
11.1, 3.7, or 1.23 nM and allowed to associate in the kinetics buffer.
Ab-gp120 association rates (on-rate, Kon) and dissociation rates (off-
rate, Koff) were measured in the kinetics buffer. The sensorgrams were
corrected with the blank reference and the binding curves were gen-
erated by global and local fitting with ForteBio Data Analysis software
package 7.0 using a 1:1 binding model when R2 values were greater
than 0.95. The affinity constant KD values (in molar units) were cal-
culated using off-rates (Koff)/on-rates (Kon). To regenerate the Protein
A sensor for reuse, the sensor was placed in wells containing regen-
erating buffer (500 mM phosphoric acid) as necessary.
Competition binding assays
The sheep gp120 C5-specific mAb, D3724 (Aalto Bio Reagents,
Dublin, Ireland) was used to coat ELISA plates at 2 mg/mL. The plates
were washed five times and blocked with PBS containing 4% whey and
5% powdered milk, and gp120 proteins were then added to these pre-
coated plates. After the five washes, the competitor rabbit mAbs or
sCD4 were diluted in the blocking buffer and added to the plates at
three-fold serial dilutions, starting at 500 mg/mL. After a 30-min
incubation, 10 mL of Ig-CD4 at 0.1 mg/mL was added to the wells.
Bound Ig-CD4 was detected as described above in the ELISA assay.
Virus capture assay
Virus capture assays were performed as previously described.31
Pseudovirions expressing the JR-FL Env and vesicular stomatitis virus
(VSV) G protein were produced with the pSG3DENV backbone in 293T
cells. Plates were coated with 50 mL of mAb at 5 mg/mL for 1 h at room
temperature and then blocked in PBS with 3% BSA overnight at 4 6C.
Hybridoma supernatants of mAb cell cultures were incubated with
pseudoviruses for 1 h before the mixtures were added to the ELISA
wells, and incubated for 3 h at room temperature. Plates were washed
five times with sterile PBS, overlaid with 10 000 TZM-bl cells per well
and incubated for 48 h at 37 6C. Luciferase activity was determined
according to the manufacturer’s instructions (Promega, Madison, WI,
USA). The competition percentage was reported as the reduction of
the luciferase signal compared to a serum negative control.
Fab production and purification
Details of the production and antigenicity characterization of rabbit
mAb R53 have been published.30 The Fab fragment of R53 was pre-
pared by papain digestion as previously described.32 Briefly, IgG was
mixed with papain (Worthington, Lakewood, NJ, USA) at a 20:1 ratio
in 100 mM Tris (pH 6.8) containing 1 mM cysteine hydrochloride and
4 mM EDTA. The mixture was incubated for 1 h at 37 6C and the
reaction was stopped by the addition of 10 mM iodoacetamide. The
Fab fragment was separated from the Fc fragment and undigested IgG
using a Protein A column and was further purified by size exclusion
chromatography. The concentration of the Fab fragment used for
crystallization was approximately 10 mg/mL.
Crystallization, data collection, structure determination
and refinement
The C4 peptide was synthesized by Biomatik (Wilmington, DE, USA)
and was dissolved in water to a concentration of 10 mg/mL.
Table 1 The inhibition percentages of R53 to outcompete binding of
mAbs to a JR-FL and VSV-G pseudotyped virus
Competing mAb
Hybridoma cell line ID
53 56 15
b12 56% 34% 24%
3074 21% 83% 17%
2G12 39% 22% 11%
Structure of mAb against HIV-1 Env C4 region
R Pan et al.
2
Emerging Microbes and Infections
A B
C D
0.8
0.6
0.4
O
D
 4
50
 n
m
Concentration (µg/mL)
Competition with lg-CD4
0.2
0.0
0.001
92
UG
03
7 (
A)
JR
-FL
 (B
)
93
MW
96
5 (
C)
92
UG
02
1 (
D)
AE
 co
ns
en
su
s (
AE
)
0.01 0.1 1 10 100 1000
R53
sCD4
R56
Clade A
Clade D
Concentration (µg/mL)
Concentration (µg/mL)
O
D
 4
50
 n
m
O
D
 4
50
 n
m
1.5
1.0
0.5
0.0
1.5
1.0
0.5
0.0
10-4 10-3 10-2 10-1 10-0
Clade B
Concentration (µg/mL)
O
D
 4
50
 n
m
1.5
1.0
0.5
0.0
10-4 10-3 10-2 10-1 10-0
Clade C
Concentration (µg/mL)
O
D
 4
50
 n
m
1.5
1.0
0.5
0.0
10-4
92UG037 (A) 96ZM651 (C)
93MW965 (C)
93TH976 (AE)
Consensus (AE)
92UG021 (D)
92US715 (B)
Bal (B)
JR-FL (B)
10-3 10-2 10-1 10-0
10-4 10-3 10-2 10-1 10-0
Clade AE
Concentration (µg/mL)
R53 epitope region
O
D
 4
50
 n
m
1.5
1.0
0.5
0.0
10-4 10-3 10-2 10-1 10-0
Figure 1 Broad reaction of R53 with gp120s of diverse clades. (A) Competition assay of R53 with Ig-CD4. The soluble CD4 (sCD4) and anti-V3mAb R56 were used as
positive and negative controls, respectively. Results shown represent themean levels of two independent experiments and error bars indicate the standard deviations.
(B) R53 bound nine gp120s from clades A, B, C, D, and AE, as revealed by ELISA. (C) Western blot analysis showed that five selected gp120 proteins from different
clades were recognized by R53. (D) A protein sequence alignment of R53 epitope region of the gp120s used in panel B and C. The R53 epitope is underlined in the JR-
FL sequence.
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Figure 2 Binding kinetics of R53 and gp120s. The binding kinetics of R53 to 92UG037 (clade A), JR-FL (clade B), 93MW965 (clade C), 92UG021 (clade D), and AE
consensus (clade AE) weremeasured using ForteBio at different concentrations of the ligand. The brown, red, blue, purple, green, and orange lines represent 300 nM,
100 nM, 33.3 nM, 11.1 nM, 3.7 nM, and 1.23 nM of gp120 proteins, respectively. Dashed gray lines represent the theoretical fitting curves. The binding data are
summarized in Table 2.
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Preliminary crystals of Fab in complex with peptide, or Fab alone, were
obtained by robotic screening using the vapor diffusion hanging drop
method. Well-diffracted crystals of R53 Fab in complex with the pep-
tide were obtained in a well solution of 24% polyethylene glycol 6000,
0.1 M citric acid, pH 5.0, and 0.02% NaN3. Crystals of R53 Fab alone
were obtained in a well solution of 14% polyethylene glycol 8000, 0.1
M HEPES, pH 7.5, and 8% ethylene glycol. Crystals of Fab R53/epitope
complex and Fab R53 alone were first soaked in the mother liquor with
additional 20% glycerol (v/v) and 20% ethylene glycol, respectively,
before being placed in the X-ray beam. X-ray diffraction data of the
crystals of Fab R53/epitope complex were collected at beam line X6A,
National Synchrotron Light Source, Brookhaven National Laboratory.
Data of the crystals of R53 Fab alone were collected at the synchrotron
beamline GM/CA CAT at the Advanced Photo Source (APS), Argonne
National Laboratory. All data sets were processed using the HKL 2000
software package,33 and structures were determined by molecular
replacement, using as the starting model the structure of another
rabbit mAb R56 that we had previously determined (Protein Data
Bank (PDB) ID 4JO1). Cycles of refinement for each model were
carried out in COOT and Phenix.34,35 The final structural analysis
was carried out using ICM, and the figures were generated using
Pymol and ICM.36,37
RESULTS
Immunological characterization of rabbit mAb R53
Rabbit mAb R53 is one of the mAbs that we recently generated from a
New Zealand white rabbit that was immunized with JR-FL DNA
prime, followed by a homologous protein boost, as previously
reported.30 The location of its epitope was mapped to the C4 region
of gp120 using a 15-aa overlapping peptide array, and a virus capture
assay was used to identify whether the epitope of R53 overlapped
functionally with those of CD4-binding sites (CD4bs) mAbs
(Table 1). CD4bs mAb b12, V3-specific mAb 3074, and glycan-specific
antibody 2G12 were used as competition targets. Supernatant from the
R53 hybridoma was able to prevent 56% of the virus binding to mAb
b12, suggesting that R53 indeed targets the CD4bs region, but not as
effectively as the CD4bs mAbs. In contrast, it could not compete
against either anti-V3 mAb 3074 or anti-glycan mAb 2G12, further
supporting its specific competition against b12. Because previously
described mAbs targeting the C4 region were found to block CD4
binding of gp120,11,26 we determined the binding specificity of R53
using a competition ELISA (Figure 1A). R53, sCD4 and R56 were used
to compete with Ig-CD4 for binding to JR-FL gp120. Here, R56 is a
rabbit mAb that was isolated from the same rabbit as that of R53, and
recognizes the V3 crown region of gp120.30,38 As expected, R53 could
inhibit Ig-CD4 binding, although it is not as effective as the positive
Table 2 R53binding kinetics with five representative gp120proteins
gp120 proteins (clade) KD (M) Kon (M
21s21) Koff (s
21)
92UG037 (A) 1.54E-09 3.41E105 5.24E-04
JR-FL (B)* 1.96E-09 1.57E105 3.09E-04
93MW965 (C) 3.98E-09 3.04E105 1.21E-03
92UG021 (D) 1.79E-09 3.56E105 6.38E-04
AE consensus (AE) 2.49E-09 3.91E105 9.73E-04
*Published in Ref. 30.
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Figure 3 Structure of the Fab R53/epitope complex. (A) A ribbon representation
of Fab R53 in complex with its epitope in a front view. The light chain, heavy chain
and the R53 epitope are colored cyan, green, andmagenta, respectively (a color-
ing scheme maintained throughout the manuscript, except where otherwise
indicated). (B) A side view of the complex. (C) A top view of the R53/epitope
complex looking at the antigen-binding site. The CDR regions are labeled and
colored differently from the rest of the Fab. (D) Electrostatic surface potentials of
R53, with red as the negatively charged and blue as positively charged regions.
The inset is the sequence of the peptide used in crystallization, with the magenta
region indicating residues visualized in the crystal structure.
Table 3 Crystallization and refinement statistics
Fab R53/epitope Fab R53
Data collection
Space group P212121 C2
Cell dimensions
a, b, c (A˚) 72.28, 84.83, 167.24 105.43, 78.55, 68.48
a, b, c (6) 90, 90, 90 90, 92.25, 90
Resolution (A˚) 2.26 (2.30–2.26) 1.63 (1.66–1.63)
Rmerge 16.5 (48.3) 5.6 (44.0)
I/sI 17.9 (3.7) 21.5 (2.3)
Completeness (%) 99.1 (97.5) 95.4 (79.0)
Redundancy 6.5 (6.1) 3.9 (3.1)
Refinement
Resolution (A˚) 44.1–2.3 31.5–1.6
Number of reflections 45616 66081
Rwork/Rfree 16.7/22.3 19.5/22.8
Number of atoms
Protein 6632 3251
Solvent 988 624
B-factors
Protein 19.8 29.9
Solvent 25.4 40.6
Root-mean-square deviations
Bond lengths (A˚) 0.008 0.007
Bond angles (6) 1.073 1.096
Values in parentheses are for the highest resolution shell.
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control sCD4. As a negative control, R56 had no impact on Ig-CD4
binding of gp120. These results confirm that R53 can block CD4
binding to gp120.
To determine the binding breadth of R53 for HIV-1 gp120 from
different clades, nine representative gp120s were tested: 92UG037.8
from clade A; 92US715, BaL, and JR-FL from clade B; 96ZM651 and
93MW965 from clade C; 92US021 from clade D; and 93TH976.17 and
AE consensus from clade AE. R53 was able to recognize all of the Envs
that were tested in the ELISA (Figure 1B). This result was verified by a
Western blot analysis, which demonstrated that the five representative
gp120s from different clades were recognized by R53 under denaturing
conditions (Figure 1C). Binding kinetics of R53 with five selective
gp120s were further determined using a ForteBio instrument
(Figure 2). R53 was shown to have high binding affinities to all five
gp120s tested, with KD values ranging from 1.79 nM to 3.98 nM
(Figure 2 and Table 2). A sequence alignment with the R53 epitope
region revealed that it is highly conserved among clades A, B, C, D, and
AE (Figure 1D).
Crystal structure of the Fab/epitope complex of rabbit mAb R53
We determined the crystal structure of the R53 antigen-binding frag-
ment (Fab) in complex with a peptide (VGKAMYAPPIRGQIR, resi-
dues 430 to 444 in HXB2 numbering). The complex structure of the
R53 Fab/epitope was solved by molecular replacement and refined to a
resolution of 2.3 A˚ with an Rwork/Rfree of 16.7%/22.3% (Figure 3 and
Table 3). The crystals grew in the orthorhombic space group P212121
with two Fab/epitope complexes in the asymmetric unit. The two
complexes are highly similar (RMSD 5 0.55 A˚); we thus chose only
one for description here. We numbered the residues following the
Kabat et al.’s convention,39 with the light and heavy chains preceded
by ‘‘L’’ and ‘‘H’’, respectively, and the residues of the epitope by a ‘‘P’’.
Although a 15-mer peptide was used in the crystallization, only 11
A
B
Figure 4 Details of the epitope binding in the Fab R53/epitope complex. (A) A stereo view of the antigen-binding site. The side chains of the key residues involved in
hydrogen bonding and van der Waals interactions (with contact areas greater than 10 A˚2) are shown in sticks. Note that (i) three tyrosines and four negatively charged
residues in R53 play a key role in binding the epitope, (ii) C4 residue ArgP440 interacts with two acidic residues AspL30 and GluL31 from the light chain, and (iii) the side
chain of C4 residue TyrP435 engages in van derWaals stacking with the antibody backbone, and its hydroxyl group forms a hydrogen bond with the side chain of GluH56
of the heavy chain. (B) A schematic of the antigen–antibody interaction. Hydrogen-binding interactions are indicated by dashed lines between the residues, whereas
van derWaals contacts are indicated by eyelashes. Residues in solid ovals contribute to the interaction by their main chain atoms, and those in dashed ovals contribute
to the interaction by their side chain atoms.
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residues, i.e., GKAMYAPPIRG (residues 431 to 441), were observed in
the electron density map. We also determined the structure of the Fab
alone (Table 3); superposition of the two Fab structures showed that
the R53 Fab appears to undergo a minimal conformational change
upon epitope binding (RMSD 5 0.77 A˚). R53 has a typical rabbit
antibody inter-domain disulfide bond between residues 80 and 170
of the light chain, which places a constraint on the variability of its
elbow angle.38
The epitope of R53 (431GKAMYAPPIRG441) does not form a regu-
lar secondary structure, but it is shaped like a stretched spring, lying
across the top of the light and heavy chains (Figure 3). Its N-terminus
sits in a groove formed by the heavy chain, while the C-terminus
straddles on a saddle formed by the R53 light chain residue AspL30,
on one side hanging the side chain of ArgP440 and on the other side the
side chain of IleP439. Electrostatic potential analysis indicates that the
antigen-binding site of R53 is negatively charged (Figure 3D), com-
plementing the positively charged epitope that harbors two positively
charged residues, LysP432 and ArgP440. All complementarity-determin-
ing regions (CDRs) are involved in antigen binding, except for the
second CDR loop of the light chain (CDR L2).
A
D E
B C
Figure 5 Locations and conformations of the R53 epitope region in gp120 structures. The structure of the R53 epitope, together with Fab R53 (only the Fv region is
shown), was superimposed onto the epitope region of gp120 structures with distinct C4 conformations, including theCD4-bound (A), b12-bound (B), F105-bound (C),
and b13-bound (D) gp120s.11,25–27 The R53 epitope is colored magenta, while gp120 is colored gray. Clashes between R53 and gp120s are indicated. The R53
epitope is accessible (without clashes between the antibody and gp120) only in the b13-bound conformation of gp120. (E) The location of theR53 epitope in the recent
published structure of BG505 SOSIP.664 trimer. The R53 epitope region, located underneath V1V2/V3, is colored magenta, while the rest of the three gp120s is
colored gray, yellow, and orange, respectively.
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Antigen–antibody interaction of R53
The antigen–antibody interaction of R53 involves extensive hydro-
phobic contacts, with ,730 A˚2 of buried surface area, and multiple
potential hydrogen bonds between the antibody and the epitope. The
epitope of R53 is comprised of six hydrophobic residues, including
AlaP433, MetP434, AlaP436, ProP437, ProP438 and IleP439, and they are
involved in several hydrophobic interactions (Figure 4).
Interestingly, the second proline residue in the epitope, ProP438, has
barely any contact with R53 (less than 5 A˚2 of calculated contact area).
The epitope residue TyrP435 has the largest contact with the antibody;
its side chain stacks in parallel with the backbone of SerL95A of CDR L3.
There are also hydrogen bonds between the epitope backbone and the
antibody: for example, TyrL32 and TyrL92 of the light chain with the
backbone of the epitope residues ProP437 and IleP439, respectively;
the backbone amide of AlaP433 with the side chain of heavy chain
residue AspH51B; the backbone of MetP434 with the amide of TyrH97;
and the OH group of the epitope residue TyrP435 with the side chain of
the heavy chain GluH55 (Figure 4).
The epitope of R53 contains no acidic residues but has two basic
residues, LysP432 and ArgP440. The side chain of LysP432 is located in an
acidic environment that is formed by AspH51B and GluH55, while the
side chain of ArgP440 forms salt bridges with two heavy chain residues,
AspL30 and GluL31, of R53 (Figure 4). The R53-contacting residues,
AM/IYAPPI, are highly conserved among clades A, B, C, D, and AE
(Figure 1D).
Spatial location of the R53 epitope in gp120 structures
After an examination of all currently available gp120 structures in the
RCSB PDB, we found that the region of the R53 epitope can form four
distinct conformations (Figure 5): (i) the CD4-bound (represented by
the first gp120 core structure with PDB ID 1GC1. The majority of the
gp120 structures, including the unbound core structures, belong to
this group), (ii) the mAb b12-bound (PDB ID 2NY7), (iii) the mAb
F105-bound (PDB ID 3HI1), and (iv) the mAb b13-bound conforma-
tions (PDB ID 3IDX).13,27–29 In the CD4-bound conformation, this
region extends from beta strand 21 of the bridging sheet to loop F13. In
the b12-bound gp120, the conformation of this region is similar to that
of the CD4-bound gp120. However, the bridging sheet is not comple-
tely formed due to the dislocation of the two strands (strands 2 and 3)
from the inner domain.29 In the b13-bound and F105-bound gp120s,
this region, as well as the region of strand 20, forms a coil.
Superimposing the R53 epitope with the C4 region in these gp120
structures showed that the epitope is only available in the b13-bound
conformation, i.e., R53 binding of the epitope does not clash with the
rest of the gp120 molecule. In a recently reported work, structures of
the stabilized BG505 SOSIP.664 trimer,2,7,8 the epitope region of R53
is covered under the variable loops V1V2 and V3, and is thus com-
pletely buried in the interior of the trimer (Figure 5E).
DISCUSSION
We have structurally defined a linear C4 epitope in complex with a
broadly reactive gp120-specific mAb to understand the antigen–anti-
body interactions in a region of gp120 that serves as a target for
many previously reported CD4 blocking mAbs, for which structural
information was previously unavailable. The epitope is located at the
C-terminus of the bridging sheet and loop F. This region plays critical
roles in gp120 functions and thus is highly conserved. Residues TyrP435,
ProP438, IleP439, ArgP440, and GlyP441 in the R53 epitope region are
critical for co-receptor binding.6,40 This region is also highly
immunogenic, as indicated by several mAbs that were reported in the
literature. However, most of the antibodies that target this region are
not neutralizing or have only weak neutralization activities,23,25,30,41,42
suggesting that this region is masked in the gp120 trimer.
Our data provide a mechanistic understanding of how this region is
masked. In the pre-fusion gp120/gp41 complex trimer, this region is
buried by V1V2 and V3 loops that lie on top of it; thus, this region is
sequestered from interactions with antibodies. In the CD4-bound
state, this region is located on the surface of the gp120 monomer
(not shown). However, in this conformation the epitope of R53 is
not available for mAb binding (Figure 5A), as the side chains of amino
acids, such as TyrP435 that binds R53, are buried and face the core of the
molecule. Thus, the high immunogenicity of this region may be
derived from the side chains that are not accessible in the CD4-bound
state. Therefore, our structure can explain the mechanism by which
this family of mAbs blocks the binding of CD4, i.e., as illustrated in
Figure 5A, the CD4-bound conformation of gp120 is not compatible
with R53 binding. In other words, the binding of the CD4-blocking
mAbs will prevent the correct formation of the CD4 binding site, thus
preventing CD4 binding to gp120.
RCSB PDB accession numbers for the crystal structures
Atomic coordinates for the R53 Fab/epitope complex and the Fab
alone have been deposited in the RCSB PDB with the accession codes
4ZTO and 4ZTP, respectively.
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